PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Yoon Jin Cha; Dooreh Kim; Soong June Bae; Sung Gwe Ahn; Joon Jeong; Hye Sun Lee; Soyoung Jeon; Tae-Kyung Yoo; Woo Chan Park; Chang Ik Yoon

doi:https://doi.org/10.1038/s41598-021-97250-2

doi.org/10.1038/s41598-021-97250-2

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

,

,

..., Chang Ik Yoon

10

Scientific Reports4.60

Volume: 11, Issue: 1

Published: Oct 1, 2021

Abstract

Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) analysis. We retrospectively investigated tumor tissues derived from 316 breast cancer cases, by constructing tissue microarrays and by performing IHC...

Paper Fields

Paper Details

Title

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

DOI

doi.org/10.1038/s41598-021-97250-2

Published Date

Oct 1, 2021

Journal

Scientific Reports

Volume

11

Issue

1

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History